A separate investigation revealed that the novel DAL4‐LNP, comprising DOPE, cholesterol, PEG, di‐amino lipid materials (DALs), and mRNA, demonstrated the ability of LNPs to safeguard mRNA sequences for effective in vivo administration, leading to significant production of anti‐human epidermal growth factor receptor 2 (HER2) antibodies in serum for a duration of 14 days (45 ± 8.6 μg/mL) following LNPs injection in breast cancer mice.110. The gene discussed is ERBB2; the disease is breast carcinoma.